Fecal microbiota transplantation in recurrent Clostridium difficile infection: A retrospective single‐center chart review
Open accessAbstract
Background and Aim Fecal microbiota transplantation (FMT) has been proposed as a treatment option for patients with recurrent Clostridium difficile (C. difficile) infection but remains a novel option. We examined if FMT is an effective means of treating recurrent C. difficile infection. Methods A retrospective review of 35 patients who underwent FMT was completed. Demographics and other variables, including the use of proton pump inhibitor therapy and history of inflammatory bowel disease, were collected. Results Twenty‐five patients (71.4%) belonged to a high‐risk population (working in a hospital setting, rehabilitation center, or nursing facility) and a total of 74.3% of patients (n = 26 patients) had no history of proton pump inhibitor use. Twenty‐five patients (71.4%) had used metronidazole prior to transplantation, 35 patients (100%) had used vancomycin, and 7 patients (20%) had used fidaxomicin for prior infection. Four patients (11.4%) had used all three antibiotics during prior treatment. Of the eight patients who had a history of inflammatory bowel disease, six (75%) experienced resolution of symptoms after transplantation. A total of 30 patients (85.7%) had resolution of their symptoms 6–8 weeks’ posttransplant, while 5 patients (14.3%) continued to have symptoms. Conclusions Our retrospective chart review supports that patients benefit from FMT in the setting of recurrent C. difficile infection.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fecal microbiota transplantation from healthy hosts is positively correlated with disease reversal, especially those stemming from gut barrier dysfunction like IBD, IBS, celiac disease, and Clostridium difficile infections.
“Studies have revealed that fecal microbiota transplantation (FMT) from healthy hosts are positively correlated with disease reversal, especially those stemming from gut barrier dysfunction like IBD, IBS, celiac disease, and Clostridium difficile infections.19,20”
From Regulation of Intestinal Barrier Function by Microbial Metabolites (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Duodenal Infusion of Donor Feces for Recurrent <i>Clostridium difficile</i>
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · see citing works
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pépin, J., & Wilcox, M. H. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,931 · see citing works
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690 · see citing works
Burden of <i>Clostridium difficile</i> Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641 · see citing works
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C. P., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy149 · Cited by 1,163 · see citing works
Breaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724 · see citing works
Kelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636 · see citing works
Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14201 · Cited by 617 · see citing works
Increase inClostridium difficile–related Mortality Rates, United States, 1999–2004
Redelings, M. D., Sorvillo, F. J., & Mascola, L. (2007) · Emerging infectious diseases · doi:10.3201/eid1309.061116 · Cited by 431 · see citing works
Epidemiology of Community-AssociatedClostridium difficileInfection, 2009 Through 2011
Chitnis, A. S., Holzbauer, S., Belflower, R., Winston, L. G., Bamberg, W., Lyons, C., Farley, M. M., Dumyati, G. K., Wilson, L. E., Beldavs, Z. G., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.7056 · Cited by 403 · see citing works
Zhang, S., Palazuelos‐Munoz, S., Balsells, E., Nair, H., Chit, A., & Kyaw, M. H. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1786-6 · Cited by 302 · see citing works
McDonald, E. G., Milligan, J., Frenette, C., & Lee, T. C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.42 · Cited by 216 · see citing works
Fecal microbiota transplantation in relapsing Clostridium difficile infection
Rohlke, F., & Stollman, N. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12453637 · Cited by 214 · see citing works
Agrawal, M., Aroniadis, O. C., Brandt, L. J., Kelly, C., Freeman, S., Surawicz, C., Broussard, E., Stollman, N., Giovanelli, A., Smith, B., et al. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000410 · Cited by 186 · see citing works
Clostridium difficile Infection: New Insights Into Management
Khanna, S., & Pardi, D. S. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.07.016 · Cited by 134 · see citing works
Consensus report: faecal microbiota transfer – clinical applications and procedures
König, J., Siebenhaar, A., Högenauer, C., Arkkila, P. E. T., Nieuwdorp, M., Norén, T., Ponsioen, C. Y., Rosien, U., Rossen, N., Satokari, R. M., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13868 · Cited by 114 · see citing works
Methods and Reporting Studies Assessing Fecal Microbiota Transplantation
Bafeta, A., Yavchitz, A., Riveros, C., Batista, R., & Ravaud, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2810 · Cited by 111 · see citing works
Review article: faecal transplantation therapy for gastrointestinal disease
Landy, J., Al-Hassi, H. O., McLaughlin, S. D., Walker, A. W., Ciclitira, P. J., Nicholls, R. J., Clark, S. K., & Hart, A. L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04737.x · Cited by 100 · see citing works
Jalanka, J., Hillamaa, A., Satokari, R. M., Mattila, E., Anttila, V., & Arkkila, P. E. T. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14443 · Cited by 64 · see citing works
Mandalia, A. B., Ward, A., Tauxe, W. M., Kraft, C. S., & Dhere, T. (2015) · International Journal of Colorectal Disease · doi:10.1007/s00384-015-2396-2 · Cited by 34 · see citing works
Fecal transplantation for the treatment of recurrentClostridium difficileinfection
Karadsheh, Z., & Sule, S. S. (2013) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.114163 · Cited by 24 · see citing works
Hota, S. S., & Poutanen, S. M. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy045 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Regulation of Intestinal Barrier Function by Microbial Metabolites
Ghosh, S., Whitley, C. S., Haribabu, B., & Jala, V. R. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.02.007 · Cited by 835 · see citing works
Aby, E. S., Vaughn, B. P., Enns, E. A., & Rajasingham, R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac207 · Cited by 28 · see citing works
- Authors
- Kim, P., Gadani, A., Abdul‐Baki, H., Mitre, R., & Mitre, M.
- Affiliations
- Allegheny General Hospital (US)
- Department of Internal Medicine and Division of Gastroenterology and Hepatology Allegheny General Hospital Pittsburgh Pennsylvania United States of America
- Corresponding author
- Kim, Pamela
- Venue
- JGH Open
- Publisher
- Wiley
- Published
- 2018-10-15
- Volume
- 3
- Issue
- 1
- Pages
- 4-9
- ISSN
- 2397-9070 (ISSN-L)
- PMC
- PMC6386733
- OpenAlex
- W2897804844
- Cited by
- 24
- References
- 22
- Citations by year
- 2025: 1 · 2024: 7 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 6
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- JGH Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, metronidazole, vancomycin, fidaxomicin, inflammatory bowel disease, proton pump inhibitors, high-risk patients, nursing home residents, rehabilitation center patients, treatment efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
